BR112017012355A2 - composição farmacêutica compreendendo composto amida heterocíclica aromática contendo nitrogênio bicíclico como ingrediente ativo - Google Patents

composição farmacêutica compreendendo composto amida heterocíclica aromática contendo nitrogênio bicíclico como ingrediente ativo

Info

Publication number
BR112017012355A2
BR112017012355A2 BR112017012355-0A BR112017012355A BR112017012355A2 BR 112017012355 A2 BR112017012355 A2 BR 112017012355A2 BR 112017012355 A BR112017012355 A BR 112017012355A BR 112017012355 A2 BR112017012355 A2 BR 112017012355A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
active ingredient
aromatic heterocyclic
compound containing
amide compound
Prior art date
Application number
BR112017012355-0A
Other languages
English (en)
Inventor
Nagashima Takeyuki
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of BR112017012355A2 publication Critical patent/BR112017012355A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composição farmacêutica compreendendo composto amida heterocíclica aromática contendo nitrogênio bicíclico como ingrediente ativo" [problema] provido é uma composição farmacêutica para tratar vários tipos de câncer em que o complexo mitocondrial i está envolvido, particularmente câncer coloretal, leucemia e/ou linfoma maligno. [meios para solução] como um resultado de intensa análise para criar uma composição farmacêutica para tratar vários tipos de câncer, os inventores da presente invenção confirmaram que um composto amida heterocíclica aromática contendo nitrogênio bicíclico específico tem o efeito de inibir o complexo mitocondrial i e ativar ampk, e que uma composição farmacêutica compreendendo o composto com um ingrediente ativo tem um efeito no tratamento em vários tipos de câncer em que complexo mitocondrial i está envolvido, particularmente câncer coloretal, leucemia e/ou linfoma maligno, e então completaram a presente a invenção.
BR112017012355-0A 2014-12-09 2015-12-08 composição farmacêutica compreendendo composto amida heterocíclica aromática contendo nitrogênio bicíclico como ingrediente ativo BR112017012355A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2014-249346 2014-12-09
JP2014-249349 2014-12-09
JP2014249347 2014-12-09
JP2014249349 2014-12-09
JP2014-249347 2014-12-09
JP2014249346 2014-12-09
PCT/JP2015/084456 WO2016093255A1 (ja) 2014-12-09 2015-12-08 二環式含窒素芳香族ヘテロ環アミド化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
BR112017012355A2 true BR112017012355A2 (pt) 2018-02-27

Family

ID=56107432

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012355-0A BR112017012355A2 (pt) 2014-12-09 2015-12-08 composição farmacêutica compreendendo composto amida heterocíclica aromática contendo nitrogênio bicíclico como ingrediente ativo

Country Status (10)

Country Link
US (1) US20170360781A1 (pt)
EP (1) EP3231426A1 (pt)
JP (1) JPWO2016093255A1 (pt)
KR (1) KR20170088880A (pt)
CN (1) CN106999489A (pt)
BR (1) BR112017012355A2 (pt)
CA (1) CA2972230A1 (pt)
MX (1) MX2017007648A (pt)
RU (1) RU2017120180A (pt)
WO (1) WO2016093255A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020008A1 (en) * 2000-09-06 2002-03-14 The Scripps Research Institute Inhibitors of nadh:ubiquinone oxidoreductase
BR112015030248A2 (pt) * 2013-06-10 2017-07-25 Astellas Pharma Inc composto de amida heterocíclica aromática contendo nitrogênio bicíclico

Also Published As

Publication number Publication date
MX2017007648A (es) 2017-10-11
US20170360781A1 (en) 2017-12-21
RU2017120180A (ru) 2019-01-11
JPWO2016093255A1 (ja) 2017-09-21
KR20170088880A (ko) 2017-08-02
EP3231426A1 (en) 2017-10-18
CA2972230A1 (en) 2016-06-16
CN106999489A (zh) 2017-08-01
WO2016093255A1 (ja) 2016-06-16

Similar Documents

Publication Publication Date Title
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CL2019001551A1 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2016000045A1 (es) Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cáncer.
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12015502028A1 (en) Ido inhibitors
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
BR112015032595A8 (pt) inibidores de ido
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
BR112017022032A2 (pt) métodos para tratamento de transtornos de armazenamento lisossômico
UY38472A (es) Moduladores de la expresión de foxp3
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112017012355A2 (pt) composição farmacêutica compreendendo composto amida heterocíclica aromática contendo nitrogênio bicíclico como ingrediente ativo
BR112018005771A2 (pt) composto, agente terapêutico ou preventivo, uso de um composto, composição farmacêutica, e, método para tratamento de alopecia areata.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]